This trial is active, not recruiting.

Condition central nervous system injury
Treatment infusion of mscs
Phase phase 0
Sponsor Fuzhou General Hospital
Start date January 2011
End date January 2014
Trial size 30 participants
Trial identifier NCT01719640, MSC-CNS


Central nervous system (CNS) injury leads to morbidity in patients, which has few good rehabilitation measures. Mesenchymal stem cells seem to have regenerative and tissue-repairing capabilities. The investigators design this study to infuse mesenchymal stem cells (MSCs) intrathecally to CNS injury patients, and observe the safety and efficacy by recording the change of nervous system scores, trying to prove the effect of MSC in rehabilitate CNS injury.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
infusion of MSCs at day 0, 7, 14, 21
infusion of mscs

Primary Outcomes

life quality score
time frame: 1y

Secondary Outcomes

adverse events
time frame: 1y

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - CNS injury > 3 months - age > 18 years - willing to give consent Exclusion Criteria: - any contradiction to intrathecal infusion - age < 18 years - CNS injury < 3 months - CNS injury > 3 years

Additional Information

Official title Intrathecal Injection of Mesenchymal Stem Cells in Central Nervous System Injury
Trial information was received from ClinicalTrials.gov and was last updated in October 2012.
Information provided to ClinicalTrials.gov by Fuzhou General Hospital.